We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




TeraRecon to Sell EnvoyAI Platform

By MedImaging International staff writers
Posted on 12 Dec 2017
Print article
Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
TeraRecon (Foster City, CA, USA), a provider of advanced visualization solutions, has entered into a distribution partnership with EnvoyAI (Cambridge, MA, USA) to sell and market the EnvoyAI platform. The platform includes a content-rich artificial intelligence (AI) marketplace, called the EnvoyAI Exchange, as well as a suite of market-ready AI-enablement technologies aimed at fostering broader access and clinical use of medical imaging algorithms within busy radiology practices.

TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.

“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”

New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Gold Member
X-Ray QA Meter
T3 RG Pro
Radiation Therapy Treatment Software Application
Elekta ONE
New
40/80-Slice CT System
uCT 528

Print article
Radcal

Channels

Radiography

view channel
Image: The new X-ray detector produces a high-quality radiograph (Photo courtesy of ACS Central Science 2024, DOI: https://doi.org/10.1021/acscentsci.4c01296)

Highly Sensitive, Foldable Detector to Make X-Rays Safer

X-rays are widely used in diagnostic testing and industrial monitoring, from dental checkups to airport luggage scans. However, these high-energy rays emit ionizing radiation, which can pose risks after... Read more

MRI

view channel
Image: Artificial intelligence models can be trained to distinguish brain tumors from healthy tissue (Photo courtesy of 123RF)

AI Can Distinguish Brain Tumors from Healthy Tissue

Researchers have made significant advancements in artificial intelligence (AI) for medical applications. AI holds particular promise in radiology, where delays in processing medical images can often postpone... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: Cleerly offers an AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque, stenosis and ischemia (Photo courtesy of Cleerly)

AI-Enabled Plaque Assessments Help Cardiologists Identify High-Risk CAD Patients

Groundbreaking research has shown that a non-invasive, artificial intelligence (AI)-based analysis of cardiac computed tomography (CT) can predict severe heart-related events in patients exhibiting symptoms... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.